CEACAM16 antibody
Principal name
CEACAM16 antibody
Alternative names for CEACAM16 antibody
CEAL2, Carcinoembryonic antigen-related cell adhesion molecule 16, Carcinoembryonic antigen-like 2
SwissProt ID
Q2WEN9 (Human)
Gene ID
388551 (CEACAM16)
Ncbi ID
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), Paraffin Sections (P), Enzyme Immunoassay (E), Flow Cytometry (F)
Background of CEACAM16 antibody
CEA-related cell adhesion molecule 16 (CEACAM16) belongs to the carcinoembryonic antigen (CEA) gene family which are widely expressed (1). The mammal-specific member CEACAM16 is well conserved and specifically expressed in the inner ear (2). It is a structural component of the tectorial membrane and the expression is necessary for hearing over an extended frequency range (3).
General readings
Zebhauser,R., (2005) Genomics 86 (5), 566-580
Human Liver; WB Suggested Anti-CEACAM16 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: Human Liver; CEACAM16 antibody - middle region (ARP44865_P050) in Human Liver cells using Western Blot
Human Brain; WB Suggested Anti-CEACAM16 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: Human brain; CEACAM16 antibody - middle region (ARP44864_P050) in Human Brain cells using Western Blot
Immunohistological staining using SU-9D5 Cat.-No AM32984PU-N on paraffin sections of cochlea tissue of an adult transgenic mouse with a human CEACAM16 gene (Ceacam16+/+ mouse cochlea). Binding of biotinylated SU-9D5 was detected with horseradish peroxidase-coupled streptavidin and stained with 3-amino-9-ethylcarbazole. Constanze Schäuble, Tumor Immunology Laboratory, LMU, Munich.
SDS-PAGE analysis of purified SU-9D5 monoclonal antibody: Lane 1: molecular weight marker, Lane 2: 2 μg of purified SU-9D5 antibody. Proteins were separated by SDSPAGE and stained with RAPID StainTM Reagent.
FACS analysis of BOSC23 cells using SU-9D5 Cat.-No AM32984PU-N. BOSC23 cells were transiently transfected with an expression vector encoding either CEACAM16 (red curve) or an irrelevant protein (control transfectant). Binding of SU-9D5 was detected with a PE- conjugated secondary antibody. A positive signal was obtained only with CEACAM16 transfected cells.
BOSC23 cells were transiently transfected with expression vectors containing either the cDNA of CEACAM1, CEACAM3, 4, 6, 8 19, or 20. Expression of the constructs was tested with monoclonal antibodies known to recognize the corresponding proteins (data not shown). An irrelevant monoclonal antibody served as a negative control (black curves). For specificity testing, protein G-purified SU-9D5 was tested on all CEACAM transfectants. A positive signal was obtained only with CEACAM16 transfected cells (red curve).
WB Suggested Anti-CEACAM16 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 312500; Positive Control: Human brain
WB Suggested Anti-CEACAM16 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 312500; Positive Control: Human Liver
- Quick-Filters:
- Cited (1)
- Highly Validated (1)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AM32984PU-N | CEACAM16 antibody |
||||||
 |
Mouse | IgG2b | SU-9D5 | Purified | Hu | E, F, P |
0.1 mg /
€380.00
|
| OriGene Technologies GmbH | |||||||
 +3 additional images |
Published recently! Highly validated antibody! |
||||||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP324965 | CEACAM16 |
||||
| Recombinant protein of human carcinoembryonic antigen-related cell adhesion molecule 16 (CEACAM16) | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY422030 | CEACAM16 overexpression lysate |
|
 |
0.1 mg /
€495.00
|
|
| OriGene Technologies, Inc. |